CDMO

Jul 22, 2026

For most of modern medical history, treatment has meant managing disease, controlling symptoms, slowing progression, and buying time. Regenerative medicine flips that model on its head. Instead of managing damage, it aims to repair it: regrowing tissue, replacing diseased cells, and in some cases, reversing conditi...

May 27, 2026

Once confined to the realm of theoretical science fiction, cell and gene therapies (CGTs) have crossed decisively into clinical and commercial reality. In less than a decade, the world has witnessed landmark approvals, from the first CAR-T cell therapies for blood cancers to gene therapies restoring vision in patie...

May 20, 2026

Plasmid DNA has moved from being a specialized laboratory tool to becoming one of the most strategic raw materials in modern biopharmaceutical manufacturing. In simple terms, a plasmid is a small, circular DNA molecule that exists separately from chromosomal DNA and can replicate independently inside microbial host...

Nov 06, 2025

Nexalin Technology Announced Regulatory Approval to Sell Gen 2 SYNC, 15 mA Neurostimulation DIFS™ Device in Israel  On October 30, 2025, Nexalin Technology, Inc., a company recognized for its Deep Intracranial Frequency Stimulation (DIFS™) technology, announced that its Gen-2 Console (“SYNC”) 15 mA neurosti...

May 17, 2022

Love Pharma Completes the Acquisition of MicroDoz Therapy LOVE Pharma Co. has announced the completion of its acquisition of MicroDoz Theraphy Inc. ("MicroDoz"). Love Pharma holds exclusive manufacturing, marketing, packaging, selling, and distribution licenses in Europe, the United Kingdom, and North America. U...

Dec 10, 2021

Contract Development and Manufacturing Organisation (CDMO) is a term for organizations providing extensive services and solutions to the pharmaceutical and biotech industry starting from the drug development process to packaging of the product. These companies deliver a broad range of services, such as clinical res...

Nov 22, 2018

Cambrex takes over Avista in USD 250 Million agreement Cambrex, life sciences company, is taking over Avista Pharma Solutions with a deal of USD 250 million to become a leading contract development and manufacturing organization (CDMO). The agreement includes the early-stage drug development and manufacturing capabi...

Feb 16, 2018

Vertex pharmaceutical’s growth story in biotech with Symdeko’s approval FDA has recently approved Vertex Pharmaceutical’s latest combination treatment, Symdeko, to serve the cystic fibrosis patient population. Symdeko's annual list price has been set at USD 292,000. Symdeko has paired with a fresh corrector, tezacaf...

Sep 16, 2016

Piramal buys another U.S. manufacturer operation India’s Piramal has decided to have a manufacturing operations based in the U.S., and has now bought another operation after it bought a sterile manufacturing operation last year. The company bought Midwestern-based CDMO for $42.95 million in cash, with an additional ...